DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital contractural arachnodactyly — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital contractural arachnodactyly maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital contractural arachnodactyly is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL (NSDHL) — NSDHL is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6JKH · 3.0 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
Congenital contractural arachnodactyly (CCA) is an uncommon condition marked by arachnodactyly, dolichostenomelia, kyphoscoliosis, crumpled auricles, and flexion contractures at knees, elbows, fingers, and sometimes other joints. A 1979 report described a newborn with CCA and roentgenographic evidence of advanced bone age; the authors noted that advanced skeletal maturity is rare in neonates and had been mentioned in only one other CCA case, so it was unknown whether it was coincidental or integral to the syndrome.
Two newborn infants with a severe form of CCA both died in the first year of life, according to a 1986 report. One child also had other anomalies not generally associated with CCA. The authors concluded that these observations were consistent with CCA being an aetiologically and clinically heterogeneous disorder. The severe form of CCA is usually associated with early mortality due to multisystem complications.
A 2006 report described a 9-year-old male child with severe skeletal manifestations of CCA who had none of the cardiovascular or gastrointestinal features described in severe CCA. He had profound intellectual disability with autism. Sequencing of all exons of FBN2, the gene associated with CCA, found no disease-causing mutation. The authors stated that when severe CCA is diagnosed in the newborn period, parents need to be aware that long-term survival is possible, particularly if no significant extraskeletal complications are present, and that significant neurodevelopmental delay may occur.
What is still missing is a clear understanding of the genetic and clinical heterogeneity that determines which newborns with severe CCA will die in infancy and which may survive long-term with neurodevelopmental disability. No treatment trials exist. No patient stratification by specific FBN2 mutation or by the presence of extraskeletal complications has been prospectively tested.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1986 · 36 citations
A severe form of congenital contractural arachnodactyly in two newborn infants
AbstractCongenital contractural arachnodactyly (CCA) is an uncommon condition characterized by arachnodactyly, dolichostenomelia, kyphoscoliosis, "crumpled" auricles, and flexion contractures at knees, elbows, fingers, and sometimes other joints. The long-term prognosis for affected individuals is usually relatively good. We report on two newborn infants with severe CCA, both of whom died in the first year of life. One child also had other anomalies not generally associated with this disorder. These observations are consistent with the possibility that CCA is an etiologically and clinically heterogeneous disorder.
American journal of diseases of children · 1979 · 8 citations
Congenital Contractural Arachnodactyly
Abstract• We report a case of congenital contractural arachnodactyly (CCA) diagnosed at birth. The newborn showed roentgenographic evidence of advanced bone age. As advanced skeletal maturity is rare in neonates and, to our knowledge, has been mentioned in only one other case of a patient with CCA, it is not known whether it is a coincidental finding or an integral part of the CCA syndrome. (Am J Dis Child133:639-640, 1979)
Long-term survival in a child with severe congenital contractural arachnodactyly, autism and severe intellectual disability
AbstractThe severe form of congenital contractural arachnodactyly is usually associated with early mortality due to multisystem complications. Here, we report a 9-year-old male child with severe skeletal manifestations of congenital contractural arachnodactyly. He had none of the cardiovascular or gastrointestinal features that have been described in severe congenital contractural arachnodactyly. He had profound intellectual disability with autism. All exons of FBN2, the gene associated with congenital contractural arachnodactyly, were sequenced and no disease-causing mutation was found. When severe congenital contractural arachnodactyly is diagnosed in the newborn period, parents need to be aware that long-term survival is possible, particularly if no significant extraskeletal complications are present, and that significant neurodevelopmental delay may occur.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
